1. SBC-5 miR-335+ xenografts abrogated completely, or in part, skeletal osteolytic lesions in humanized NOD/SCID IL2Rγnull immunodeficient mice.
SBC-5 miR-335+ xenografts abrogated completely, or in part, skeletal osteolytic lesions in humanized NOD/SCID IL2Rγnull immunodeficient mice. SBC-5 miR-335+ cells, SBC-5 miR-29a+ cells, or control (SBC-5 VectorCtrl) cells at 106 cells/mouse were injected intravenously into the tail vein of 8-week-old NOD/SCID IL2Rγnull mice (n = 10/group). A, representative radiographs from a mouse in each group at 28 days after injection. Arrows indicate osteolytic “metastatic” lesion. B, osteolytic bone lesions in the spine, femur, tibia, and ulna bones of each mouse were counted using the radiographs. Although both SBC-5 miR-335+ and SBC-5 miR-29a+ xenografts induced fewer osteolytic lesions than controls, the reduction was significant only in miR-335+ xenografts. C, frequency distribution of osteolytic lesions revealed that no lesions developed from 3 SBC-5 miR-335+ xenografts, and the remaining 7 SBC-5 miR-335+ mice exhibited fewer lesions than controls. The number of osteolytic lesions from SBC-5 miR-29a+ xenografts did not differ significantly from control (compared with control, **, P < 0.01).
Meng Gong et al. Mol Cancer Res 2014;12:
©2014 by American Association for Cancer Research